3 min read
Measuring What Can't Be Seen: How PTSD Clinical Trials Prove a Drug Works
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
Veristat Announces Participation in the "Triangle Perspective on AI, ML, & the Future of Drug Development" Panel Discussion
Veristat is excited to announce that our Chief Commercial Officer, Rachel Page, will be a panelist in the upcoming event organized by Sterling Bay, "Triangle Perspective on AI, ML, & the Future of Drug Development." This engaging panel discussion will feature five leading life sciences executives and two highly accomplished moderators examining the transformative impact of artificial intelligence (AI) and machine learning (ML) on the future of drug development.
Event Details:
Date and Time: Wednesday, July 17, 2024, 9:00 AM to 9:50 AM ET USA
Format: Webinar via Zoom (Zoom link will be distributed prior to the webinar. The session will be recorded and made available for those unable to attend live.)
Registration: Register Here
Panel Discussion Highlights:
The panel will focus on how AI/ML developments are revolutionizing the global biopharmaceutical industry, with a particular emphasis on the life sciences sector in North Carolina and the Research Triangle. Topics covered will include drug discovery, development, and deployment.
Panelists:
Rachel Page, Chief Commercial Officer, Veristat
Joe Webb, Chief Executive Officer & Founder, Vitality Robotics
Julie Blasingim, Chief Executive Officer, Univo IRB
Mark Sydnor, President, Network Partners Group
Robin Hyde-DeRuyscher, President and Chief Scientific Officer, Emergo Therapeutics
Co-Moderators:
Kate Pestrichelli, Vice President, Program Management, Network Partners Group Stephanie Gaulding, Managing Director, Pharmatech Associates, a USP company
MC:
Michael Daniel, MSChE, Product Development Consultant, Pharma & CG Industries
Join Us:
Don't miss this opportunity to gain insights from industry leaders about the future of drug development in the age of AI and ML. We encourage you to register and invite others to attend this informative session.
We look forward to seeing you there and sharing how Veristat is contributing to advancements in the life sciences industry.
Registration: Register Here
Schedule A Meeting
Interested in meeting with Rachael Page, Chief Commercial Officer at Veristat, Complete the form below
Event Topics:
3 min read
The Psychedelic Setback: What MDMA Rejection Taught Drug Developers
Apr 24, 2026 Veristat Blog
In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision...